基石药业-B(2616.HK)逆势大涨超9%
格隆汇8月26日丨有1608.67万股限售股今日迎来解禁(港股首发)的基石药业-B(2616.HK)逆势大涨,现报10.98港元,涨9.15%,暂成交648万港元,最新总市值111亿港元。

基石药业-B(2616.HK)22日发公告称,抗肿瘤抑制剂CS3002已在澳洲完成I期试验备案,相关研究即将开展。而中国临床肿瘤学会2019年年会(CSCO 2019年年会)已接受该公司三款肿瘤免疫治疗骨干候选药物CS1001(抗PD-L1单抗)、CS1002(抗CTLA-4单抗)及 CS1003(抗PD-1单抗)的三项临床研究摘要。同时,CS1001-101 Ib期临床研究的其它三项最新突破性研究摘要也已递交以供展示。
此外,公司今日发公告称,由基石药业合作伙伴Blueprint Medicines Corporation (纳斯达克股份代号:BPMC) 开发的avapritinib的 I/II期桥接注册性试验实现中国首例受试者给药。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.